Candidiasis in COVID-19 Patients
Novelty in Biomedicine,
Vol. 9 No. 2 (2021),
10 June 2021
,
Page 101-103
https://doi.org/10.22037/nbm.v9i2.34133
Abstract
Based on previous studies, some comorbidities influence the morbidity and mortality of COVID-19 disease. Among these factors, opportunistic fungal infections could have a major impact on the mortality of COVID-19 patients.
- COVID-19, Candidiasis, CNS fungal infections
How to Cite
References
Rod J, Oviedo-Trespalacios O, Cortes-Ramirez J. A brief-review of the risk factors for covid-19 severity. Revista de saude publica. 2020;54:60.
Salehi M, Ahmadikia K, Badali H, Khodavaisy S. Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran. Mycopathologia. 2020;185(4):607-11.
Tian W, Zhang N, Jin R, Feng Y, Wang S, Gao S, et al. Immune suppression in the early stage of COVID-19 disease. Nature communications. 2020;11(1):1-8. doi: 10.1038/s41467-020-19706-9
Shoham S, Levitz SM. The immune response to fungal infections. British journal of haematology. 2005;129(5):569-82.
Sharma RR. Fungal infections of the nervous system: current perspective and controversies in management. International Journal of Surgery. 2010;8(8):591-601. doi: 10.1016/j.ijsu.2010.07.293
Góralska K, Blaszkowska J, Dzikowiec M. Neuroinfections caused by fungi. Infection. 2018;46(4):443-59.
Silva LN, de Mello TP, de Souza Ramos L, Branquinha MH, Roudbary M, Dos Santos ALS. Fungal Infections in COVID-19-Positive Patients: A Lack of Optimal Treatment Options. Current topics in medicinal chemistry. 2020;20(22):1951-7.
Nori P, Cowman K, Chen V, Bartash R, Szymczak W, Madaline T, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infection Control & Hospital Epidemiology. 2021;42(1):84-8.
Agrifoglio A, Cachafeiro L, Figueira JC, Añón JM, de Lorenzo AG. COVID-19 and fungal co-infections: we must keep them in mind. Journal de Mycologie Medicale. 2020.
Seitz T, Hoepler W, Weseslindtner L, Aberle J, Aberle S, Puchhammer-Stoeckl E, et al. Successful management of the first reported case in Austria of COVID-19 with ARDS. Infection. 2020;48(4):647-51.
Cataldo MA, Tetaj N, Selleri M, Marchioni L, Capone A, Caraffa E, et al. Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming “collateral effect”. Journal of Global Antimicrobial Resistance. 2020.
Hughes S, Troise O, Donaldson H, Mughal N, Moore LS. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clinical Microbiology and Infection. 2020;26(10):1395-9.
Pemán J, Ruiz-Gaitán A, García-Vidal C, Salavert M, Ramírez P, Puchades F, et al. Fungal co-infection in COVID-19 patients: Should we be concerned? Revista iberoamericana de micologia. 2020;37(2):41-6.
Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, et al. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmunity reviews. 2020;19(7):102564. doi: 10.1016/j.autrev.2020.102564
Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clinical Microbiology and Infection. 2020.
Roodsari SR, Arab-Mazar Z. What is the Role of the Anti-Parasitic Drugs in the Treatment of Coronavirus Disease 2019?. Journal of Biomolecular Structure and Dynamics. 2020;1:14.
- Abstract Viewed: 377 times
- 1 Downloaded: 287 times